Related Experiment Video

Updated: Jul 4, 2026

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies

Jared N Silver1, Terence R Flotte

  • 1University of Florida College of Medicine, Department of Pediatrics, Gainesville, FL 32607, USA. jsilver007@yahoo.com

Pharmacogenomics
|July 4, 2008
PubMed

Insights

Adenosine deaminase deficiency severe combined immune deficiency (ADA-SCID) is a rare pediatric disorder. Alternative gene therapy using adeno-associated virus vectors offers a promising new approach to treat ADA-SCID.

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • Adenosine deaminase deficiency causes severe combined immune deficiency (ADA-SCID), a rare pediatric disorder.
  • ADA-SCID presents with immune dysfunction, infections, and multi-organ pathology.
  • Current treatments include enzyme replacement and bone marrow transplantation.

Purpose of the Study:

  • To review adenosine deaminase deficiency severe combined immune deficiency (ADA-SCID).
  • To discuss traditional treatments and retroviral gene therapies for ADA-SCID.
  • To explore alternative adeno-associated virus (AAV) vector-based gene therapies for ADA-SCID.

Main Methods:

  • Literature review of ADA-SCID treatments.
  • Analysis of retroviral gene therapy approaches and their limitations.
  • Examination of in vivo AAV vector strategies for ADA-SCID.

Main Results:

  • Retroviral gene therapies have shown success but carry risks like insertional mutagenesis.
  • In vivo AAV gene therapy offers potential for widespread tissue expression of adenosine deaminase.
  • AAV vectors present a promising alternative for ADA-SCID treatment.

Conclusions:

  • ADA-SCID requires innovative therapeutic strategies.
  • AAV-based gene therapy represents a potentially safer and effective alternative for ADA-SCID.
  • Further research into AAV vectors can advance ADA-SCID treatment.

More Related Videos

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina09:50

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina

Published on: December 25, 2021

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...